179 related articles for article (PubMed ID: 22649145)
1. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Blumenfeld Z
J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
[No Abstract] [Full Text] [Related]
2. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.
Tomao F; Benedetti Panici P; Tomao S
J Clin Oncol; 2012 Sep; 30(26):3310-1; author reply 3312-3. PubMed ID: 22649128
[No Abstract] [Full Text] [Related]
3. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer.
Saloustros E; Stratakis CA
J Clin Oncol; 2012 Sep; 30(26):3311-2. PubMed ID: 22649148
[No Abstract] [Full Text] [Related]
4. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?
Partridge AH
J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046
[No Abstract] [Full Text] [Related]
5. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
6. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
7. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.
Caruso M; Castiglione G; Aiello R; Alí M; Chiarenza M; Dimarco R; Fallica G; Di Leo MG; Sanó MV; Taibi E; Zacchia A; Miano E; Caruso F
Future Oncol; 2015; 11(23):3109-12. PubMed ID: 26544787
[No Abstract] [Full Text] [Related]
8. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
Dellapasqua S; Gray KP; Munzone E; Rubino D; Gianni L; Johansson H; Viale G; Ribi K; Bernhard J; Kammler R; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Colleoni M;
J Clin Oncol; 2019 Feb; 37(5):386-395. PubMed ID: 30589600
[TBL] [Abstract][Full Text] [Related]
9. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial.
Elgindy EA; El-Haieg DO; Khorshid OM; Ismail EI; Abdelgawad M; Sallam HN; Abou-Setta AM
Obstet Gynecol; 2013 Jan; 121(1):78-86. PubMed ID: 23262931
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
[TBL] [Abstract][Full Text] [Related]
11. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori F; Demeestere I
Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
[No Abstract] [Full Text] [Related]
12. Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors: Hopeful Though Modest Long-term Results.
Partridge AH
JAMA; 2015 Dec 22-29; 314(24):2625-7. PubMed ID: 26720024
[No Abstract] [Full Text] [Related]
13. Evaluating triptorelin as a treatment option for breast cancer.
Ferraro E; Trapani D; Marrucci E; Curigliano G
Expert Opin Pharmacother; 2019 Oct; 20(15):1809-1818. PubMed ID: 31500470
[No Abstract] [Full Text] [Related]
14. [Role of ovarian suppression in the combined treatment of breast cancer patients in premenopause].
Shchepotin IB; Zotov AS; Liubota RV; Anikus'ko NF; Liubota II
Vopr Onkol; 2013; 59(3):397-404. PubMed ID: 23909046
[No Abstract] [Full Text] [Related]
15. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin.
Meattini I; Saieva C; Meacci F; Scotti V; De Luca Cardillo C; Desideri I; Baldazzi V; Mangoni M; Scoccianti S; Detti B; Simontacchi G; Nori J; Orzalesi L; Sanchez L; Casella D; Bernini M; Fambrini M; Bianchi S; Livi L
Future Oncol; 2016 Mar; 12(5):625-35. PubMed ID: 26837239
[TBL] [Abstract][Full Text] [Related]
16. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.
Jonat W
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S23-6: discussion S33-5. PubMed ID: 12353820
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
18. Questioning GnRH analogs for gonadal protection in cancer patients.
Oktay K; Sönmezer M
Fertil Steril; 2009 Aug; 92(2):e32; author reply e34. PubMed ID: 19646599
[No Abstract] [Full Text] [Related]
19. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma.
Blumenfeld Z; Dann E
J Clin Oncol; 2013 Oct; 31(29):3721. PubMed ID: 24002509
[No Abstract] [Full Text] [Related]
20. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide.
Karimi-Zarchi M; Forat-Yazdi M; Vafaeenasab MR; Nakhaie-Moghadam M; Miratashi-Yazdi A; Teimoori S; Dehghani-Tafti A
Eur J Gynaecol Oncol; 2014; 35(1):59-61. PubMed ID: 24654464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
